The size of the European Intraocular Lens Market is forecasted to grow at a steady CAGR between 2021 to 2026.
Y-O-Y growth in the incidence of cataracts, particularly in diabetic people, is predicted to increase the enhanced superior intraocular lens, which is estimated to drive market growth for the European IOL market. An estimated 34 million people in the European Union (EU) are strained by age-related macular degeneration, as reported by EURETINA in 2017. Another source stated, according to the European Society of Retinal Specialists, the occurrence rate of age-related macular degeneration was accounted for nearly 32.8% in Germany in 2017.
The number of eye clinics and hospitals in the European countries is significantly increasing, along with the patient population getting affected by eye-related disorders such as cataracts, blindness, or diabetic retinopathy. The factor mentioned above is expected to return massive fuel to the intraocular lens market in the European region.
The costs associated with the intraocular lens are a bit expensive and not affordable to everyone in the European population, which is expected to slightly hamper the market growth. Also, the poor reimbursement policies present in this region and the deficit of proper coverage for premium IOLs are likely to disturb the growth rate of the European IOL market.
This research report on the Europe Intraocular Lens Market has been segmented and sub-segmented into the following categories:
By Material:
By Type:
By End User:
By Country:
Based on the region, Europe is assumed as a developed market and is anticipated to witness significant growth in the forecast period. The market in Europe is driven by factors such as the growing number of ophthalmic disorders and an increase in the aging population in European countries. Germany is one of the leading regions in the European IOL market. The appearance of improved healthcare amenities and increasing new product launches are the factors propelling the market growth. The government's growing number of steps in eradicating blindness and regular increase of cataracts, particularly in aged people, is likely to boost the region's IOL market growth over the assessment period. The companies are introducing novel and enhanced premium IOLs for treating patients suffering from eye disorders. For example, in May 2020, Bausch +Lomb has invented its first extended depth of IOL, LuxSmart, in Europe. Moreover, advanced technologies for treating people with eye ailments are influencing the IOL market growth.
Prominent Companies leading the Europe Intraocular Lens Market Profiled in the Report are Johnson & Johnson, Valeant, Carl Zeiss Meditec AG, Rayner, Alcon, Inc. (a division of Novartis AG), EyeKon Medical, Inc., Lenstec, Inc., HumanOptics AG, STAAR Surgical, PhysIOL s.a., Calhoun Vision Center, and Oculentis GmBH.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 Epidemiology
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 Material
5.1.1 Introduction
5.1.2 Polymethylmethacrylate (PMMA)
5.1.3 Silicone
5.1.4 Hydrophobic Acrylic
5.1.5 Y-o-Y Growth Analysis, By Material
5.1.6 Market Attractiveness Analysis, By Material
5.1.7 Market Share Analysis, By Material
5.2 Type
5.2.1 Introduction
5.2.2 Monofocal Intraocular Lens
5.2.3 Premium Intraocular Lens
5.2.3.1 Toric Intraocular Lens
5.2.3.2 Multifocal Intraocular Lens
5.2.3.3 Accommodating Intraocular Lens
5.2.3.4 Others
5.2.3.4.1 Blue Light Filtering Intraocular Lens
5.2.3.4.2 Phakic Intraocular Lens
5.2.3.4.3 Aspheric Intraocular Lens
5.2.4 Y-o-Y Growth Analysis, By Type
5.2.5 Market Attractiveness Analysis, By Type
5.2.6 Market Share Analysis, By Type
5.3 End-User
5.3.1 Introduction
5.3.2 Hospitals
5.3.3 Ambulatory Surgery Centers
5.3.4 Ophthalmology Clinics
5.3.5 Eye Research Institutes
5.3.6 Y-o-Y Growth Analysis, By End User
5.3.7 Market Attractiveness Analysis, By End User
5.3.8 Market Share Analysis, By End User
6. Geographical Analysis
6.1 Introduction
6.1.1 Regional Trends
6.1.2 Impact Analysis
6.1.3 Y-o-Y Growth Analysis
6.1.3.1 By Geographical Area
6.1.3.2 By Material
6.1.3.3 By Type
6.1.3.4 By End User
6.1.4 Market Attractiveness Analysis
6.1.4.1 By Geographical Area
6.1.4.2 By Material
6.1.4.3 By Type
6.1.4.4 By End User
6.1.5 Market Share Analysis
6.1.5.1 By Geographical Area
6.1.5.2 By Material
6.1.5.3 By Type
6.1.5.4 By End User
6.2 U.K
6.3 Spain
6.4 Germany
6.5 Italy
6.6 France
6.7 Rest of Europe
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 Johnson & Johnson
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Financial analysis
8.1.4 Recent Developments
8.1.5 SWOT analysis
8.1.6 Analyst View
8.2 Carl Zeiss Meditec AG
8.3 Rayner
8.4 EyeKon Medical, Inc
8.5 HumanOptics AG
8.6 STAAR Surgical
8.7 HOYA GROUP
8.8 Alcon, Inc.
8.9 Valeant
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, Collaborations, and Joint Ventures
9.4 New Product Launches
10. Market Outlook and Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
Related Reports
Apr 2021
